51KA Stock Overview
Operates as a regenerative medicine company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AVITA Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.10 |
| 52 Week High | US$16.70 |
| 52 Week Low | US$7.00 |
| Beta | 1.54 |
| 11 Month Change | 32.24% |
| 3 Month Change | 47.56% |
| 1 Year Change | 26.04% |
| 33 Year Change | -2.42% |
| 5 Year Change | n/a |
| Change since IPO | -43.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 51KA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 9.0% | -0.7% | 0.2% |
| 1Y | 26.0% | -17.2% | 8.5% |
Return vs Industry: 51KA exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 51KA exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 51KA volatility | |
|---|---|
| 51KA Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 51KA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 51KA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 207 | Jim Corbett | www.avitamedical.com |
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time.
AVITA Medical, Inc. Fundamentals Summary
| 51KA fundamental statistics | |
|---|---|
| Market cap | €336.01m |
| Earnings (TTM) | -€55.05m |
| Revenue (TTM) | €57.66m |
5.8x
P/S Ratio-6.1x
P/E RatioIs 51KA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 51KA income statement (TTM) | |
|---|---|
| Revenue | US$60.04m |
| Cost of Revenue | US$8.61m |
| Gross Profit | US$51.43m |
| Other Expenses | US$108.75m |
| Earnings | -US$57.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | 85.66% |
| Net Profit Margin | -95.47% |
| Debt/Equity Ratio | 348.0% |
How did 51KA perform over the long term?
See historical performance and comparison